Eyegate Pharmaceuticals (NASDAQ: EYEG) is one of 103 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Eyegate Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.
This is a summary of current ratings for Eyegate Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eyegate Pharmaceuticals Competitors||863||3773||6736||179||2.54|
Eyegate Pharmaceuticals currently has a consensus target price of $7.00, indicating a potential upside of 554.21%. As a group, “Pharmaceuticals” companies have a potential upside of 22.06%. Given Eyegate Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eyegate Pharmaceuticals is more favorable than its competitors.
Volatility & Risk
Eyegate Pharmaceuticals has a beta of 3.26, suggesting that its stock price is 226% more volatile than the S&P 500. Comparatively, Eyegate Pharmaceuticals’ competitors have a beta of 36.02, suggesting that their average stock price is 3,502% more volatile than the S&P 500.
Valuation & Earnings
This table compares Eyegate Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Eyegate Pharmaceuticals||$670,000.00||-$13.34 million||-0.91|
|Eyegate Pharmaceuticals Competitors||$8.17 billion||$1.09 billion||108.64|
Eyegate Pharmaceuticals’ competitors have higher revenue and earnings than Eyegate Pharmaceuticals. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
13.1% of Eyegate Pharmaceuticals shares are held by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are held by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Eyegate Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eyegate Pharmaceuticals Competitors||-2,433.75%||-70.11%||-7.93%|
Eyegate Pharmaceuticals competitors beat Eyegate Pharmaceuticals on 8 of the 12 factors compared.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.